This article has been corrected: Due to an entry error found in one of the triplicate data for the 48-h time-point of stability in human serum in vitro, the half-life for drug release has been corrected to 18.82 h from the stated 23.98 h in Figure 1C. The corrected Figure 1C is shown below. The authors declare that these corrections do not change the results or conclusions of this paper.
Figure 1. Structures of irinotecan, SN-38, and CL2A-SN-38.
(C) In vitro serum stability of IMMU-132 in monkey or human serum.
Original article: Oncotarget. 2015; 6:22496–22512. 22496-22512. https://doi.org/10.18632/oncotarget.4318